Using TumorGlow for imaging solid tumors during surgery
Official title: A Study to Evaluate the Safety and Efficacy of Indocyanine Green for Intraoperative Molecular Imaging of Solid Tumors (TumorGlow™)
Run by University of Pennsylvania · NCT04723810 · Data updated 2026-11-12
This study is testing a special dye to see if it can help doctors see solid tumors better during surgery, so they can remove more cancer and improve patient outcomes.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | August 14, 2024 |
| Main results expected | January 14, 2027 |
| Study ends | January 14, 2027 |
| Registry record updated | March 9, 2026 |
| Trial ID | NCT04723810 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with solid tumors or diseased tissue that are resectable and at risk for recurrence.
✕Probably not a fit
Patients who are unable to provide informed consent or have uncontrolled hypertension may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 1/2 study evaluates the safety and efficacy of using indocyanine green for intraoperative molecular imaging in patients with solid tumors or diseased tissue. The trial focuses on individuals who are surgical candidates and have tumors that are presumed to be resectable but at risk for recurrence. By enhancing the visualization of tumors during surgery, the study aims to improve surgical outcomes and reduce the likelihood of leaving residual cancerous tissue behind.
Why it matters
Potential benefit: If successful, this approach could lead to more effective tumor resections and improved patient outcomes in cancer surgery.
How similar studies have gone: Other studies using intraoperative imaging techniques have shown promise, suggesting potential success for this novel approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients 18 years of age or older. * Patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment. * Good operative candidate as determined by the treating physician and/or multidisciplinary team. * Subject capable of giving informed consent. Exclusion Criteria: * Subject unable to participate in the consent process. * Vulnerable population including pregnant women, prisoners, and children. * History of uncontrolled hypertension (e.g., history of an ER admission for hypertensive crisis or ≥ 3 blood pressure medications) * Patients with a self-reported history of iodide allergies.
Where it's running
-
University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Study coordinator: Azra Din
- Email: azra.din@pennmedicine.upenn.edu
- Phone: 215-615-7980
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Carbon nanoparticle‑loaded iron for advanced solid tumors
This test uses direct injections of a carbon nanoparticle‑loaded iron medicine (CNSI‑Fe) to see if it can shrink tumors in adults with advanced solid cancers who have no effective standard treatment options.
-
RGL-270 vaccine alone or with adebelimab to lower risk of cancer coming back after surgery
This phase I trial will test whether a personalized mRNA vaccine called RGL-270, given alone or with the immune drug adebelimab, can help prevent recurrence in adults who had radical treatment for high‑risk malignant solid tumors.
-
Evaluating XNW29016 Tablets for Advanced Solid Tumors After Standard Treatment Failure
This study is testing if XNW29016 tablets can help people with advanced solid tumors who haven't responded to regular treatments.
-
Evaluating AD1208 for advanced solid tumors
This study is testing a new drug called AD1208 to see if it is safe and tolerable for people with advanced solid tumors.
-
Nutritional management for children with solid tumors
This study is testing a new nutrition plan to see if it helps children with solid tumors get better nutrition and improve their health.
-
Treatment for advanced solid tumors using engineered T cells
This study is testing a new treatment using specially designed T cells to see if it can help people with advanced solid tumors that haven't responded to other therapies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.